An Emergency Department Intervention for Linking Pediatric Suicidal Patients to Follow-Up Mental Health Treatment
Supplemental Material
pss_62_11_1303_ds001.pdf (12 KB)
pss_62_11_1303_ds002.pdf (58 KB)
pss_62_11_1303_info.docx (12 KB)
The American Psychiatric Association (APA) has updated its Privacy Policy and Terms of Use, including with new information specifically addressed to individuals in the European Economic Area. As described in the Privacy Policy and Terms of Use, this website utilizes cookies, including for the purpose of offering an optimal online experience and services tailored to your preferences.
Please read the entire Privacy Policy and Terms of Use. By closing this message, browsing this website, continuing the navigation, or otherwise continuing to use the APA's websites, you confirm that you understand and accept the terms of the Privacy Policy and Terms of Use, including the utilization of cookies.
×pss_62_11_1303_ds001.pdf (12 KB)
pss_62_11_1303_ds002.pdf (58 KB)
pss_62_11_1303_info.docx (12 KB)
This work was funded by grant CCR921708 from the Centers for Disease Control and Prevention. Additional support was provided by grants R01 MH082856 and P30MH082760 from the National Institute of Mental Health and by a grant from the American Foundation for Suicide Prevention. The authors thank the youths, families, staff, and colleagues who made this project possible. In addition, the authors thank Lily Zhang for her contributions to data management and analysis and Donald Guthrie, Ph.D., Gabrielle Carlson, M.D., and Lisa Jaycox, Ph.D., for serving on the Data Safety and Management Board. Manuals can be obtained from the first author.
Dr. Asarnow reports receiving honoraria from Hathaways-Sycamores, Casa Pacifica, the California Institute of Mental Health, and the Melissa Institute. Dr. Piacentini has received royalties from Oxford University Press for treatment manuals and from Guilford Press and the American Psychological Association Press for books on child mental health. In addition, he has received a consultancy fee from Bayer Schering Pharma. The other authors report no competing interests.